TABLE 5

Studies reporting treatment effects (improvement/stabilisation) of corticosteroids and immunosuppressive drugs for chronic forms of DM- or PM-associated ILD

First author [ref.]	Year	Total ILD subjects n	Series	Country	CS alone	AZA	MTX	CSA	FK506	CYC	RTX	MMF	CYC then AZA
Fujisawa [86]^#	2005	20	DM/PM	Japan	7/21	7/8		6/10		3/8
Schnabel [92]	2003	10	DM/PM	Germany	6/6	2/2	2/2	1/1
Takada [93]	2005	18	DM/PM	Japan				14/14^§	4/4^ƒ
Wilkes [94]	2005	12	ARS-ILD	USA					12/12^§
Yamasaki [95]	2007	17	CADM/DM/PM	Japan					1/1^ƒ		6/8 9/9^§
Ideura [96]	2007	9	CADM	Japan	2/8			5/5^§		1/1^§
Hayashi [83]	2008
Kotani [97]	2008	16	DM	Japan				3/4
Sem [98]	2009	8	ARS-ILD	Norway							1/1 7/7^§
Tillie-Leblond [63]	2008	17	ARS-ILD	France	5/5
Marie [99]	2012	5	ARS-ILD	France							5/5^ƒ
Koreeda [100]	2010	13	ARS-ILD	Japan	6/6	1/1		4/5
Morganroth [101]	2010	4	CADM/DM	USA								3/3 1/1^§
Marie [102]^¶	2011	117	PM/DM	France	50/56	20/21 0/7^§				11/20		4/6^ƒ	6/6
Marie [59]⁺	2013	66	ARS-ILD	France	28/31	7/11				7/7		2/2^§	1/6
Cavagna [103]	2013	10	ARS-ILD	Italy				10/10^§

Data are presented as improvement/stabilisation n/N, unless otherwise stated. DM: dermatomyositis; PM: polymyositis; ILD: interstitial lung disease; CS: corticosteroids; AZA: azathioprine; MTX: methotrexate; CSA: cyclosporin A; FK506: tacrolimus; CYC: cyclophosphamide; RTX: rituximab; MMF: mycophenolate mofetil; ARS-ILD: anti-tRNA synthetase positive ILD; CADM: clinically amyopathic dermatomyositis. ^#: probably encompassing rapidly progressive ILD (RP-ILD); ^¶: includes nine RP-ILD; ⁺: includes 12 RP-ILD; ^§: second line; ^ƒ: third line.